Impact of Disease History on the Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study

Main Article Content

Brett King
Yale University School of Medicine

Wilma Bergfeld
Cleveland Clinic

Pawel Brzewski
Collegium Medicum, Jagiellonian University, Department of Dermatology

Özge Aşkin
Cerrahpaşa Medical Faculty, Department of Dermatology and Venerology, Istanbul University-Cerrahpaşa

Thierry Passeron
Université Côte d’Azur, CHU Nice, Department of Dermatology

Simaran Randhawa
Pfizer Inc

Ernest Law
Pfizer Inc

Roger A Edwards
Health Services Consulting Corporation

Robert Wolk
Pfizer Inc

Samuel H Zwillich
Pfizer Inc

Alexandre Lejeune
Pfizer Inc

Keywords

alopecia areata, efficacy, ritlecitinib, ALLEGRO, clinical trial

References

1. Islam N, et al. Autoimmun Rev. 2015;14:81-89

2. King B, et al. Poster presented at: 30th Annual EADV Meeting; September 29-October 2, 2021

3. Liu LY, et al. JAAD. 2017;76:22-28

4. King BA, et al. JAAD. 2022;86:359-364

5. Meah N, et al. JAAD. 2021;84:1594-1601.

Article Sidebar

Poster PDF
Published
Nov 16, 2022
DOI https://doi.org/10.25251/skin.6.supp.101

Article Details

How to Cite
[1]
King, B., Bergfeld, W., Brzewski, P., Aşkin, Özge, Passeron, T., Randhawa, S., Law, E., Edwards, R.A., Wolk, R., Zwillich, S.H. and Lejeune, A. 2022. Impact of Disease History on the Efficacy of Ritlecitinib (PF-06651600) in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s101. DOI:https://doi.org/10.25251/skin.6.supp.101.
Issue
Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Section
Alopecia
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>